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Brief summary 
Atrial fibrillation is known as one of major causes of increased cardiovascular mortality and 
ischemic stroke. Especially at the preclinical stage, the potential benefit of appropriate 
screening and preventive intervention to patients with increased stroke risk may be expected. 
In this review article, we will discuss the importance and future perspectives of population 
screening for atrial fibrillation. 
 
Abstract 
Atrial fibrillation (AF) is a common and progressive heart rhythm disorder that causes 
structural, functional and electrical remodelling of the heart. Although we do not fully 
understand AF yet, this arrhythmia is one clinical feature of a syndrome that is represented by 
irregularly irregular atrial rhythm accompanied by progressive atrial structural and functional 
remodelling. Although ischemic stroke, most feared complication of AF, can be prevented by 
anticoagulation, asymptomatic or paroxysmal nature of AF makes timely diagnosis of AF 
difficult. Thus, appropriate screening method for AF is necessary. In this review, we will 
discuss the importance and future perspectives of population screening for AF. 
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Introduction 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and its global 
prevalence is increasing1, 2. Serious subsequent complications such as ischemic stroke, 
deterioration of heart function, increased mortality, and impaired quality of life are medically 
important problems with social and public health implications1-5. 
Indeed, in patients with clinically diagnosed AF, appropriate stroke prevention is possible, but 
only if AF is detected prior to ischemic stroke onset6. Unfortunately, stroke can be the first 
presentation of AF, which can be a double problem, given that AF-associated strokes are 
associated with a worse prognosis (more often fatal or disabling) compared to non-AF 
associated strokes. As such, the early identification of patients at high risk of AF-associated 
strokes, and the initiation of stroke-prevention therapies can be critical7, 8. 
In this review, we will discuss the importance and future perspectives of population screening 
for AF. 
 
Observations on AF associated stroke 
AF related strokes are generally thromboembolic, but it is impossible to fully explain all 
strokes associated with AF as being associated with blood stasis during AF episodes. An 
analysis of the temporal relationship between the time of stroke onset and AF events recorded 
in cardiac implanted electric devices (CIEDs) reveals that only 8–30% of patients have AF 
detected in 30 days before the stroke onset and up to 15% of patients have AF detected only 
after stroke onset9-11. Regardless of the temporal association between AF episode and stroke 
onset, device-detected AF results in a ~2.5 fold increased stroke risk, the necessity of 
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anticoagulation might be carefully determined where stroke risk factors are present12-14. 
In the classification of ischemic stroke, Trial of Org 10172 in Acute Stroke Treatment 
classification is widely used and denotes five subtypes of ischemic stroke: (i) large-artery 
atherosclerosis, (ii) cardio-embolism, (iii) small-vessel occlusion, (iv) stroke of other 
determined aetiology, and (v) stroke of undetermined etiology15. Cryptogenic stroke, or 
known as Embolic Strokes of Undetermined Source (ESUS), are defined as: (i) non-lacunar 
brain infarct on imaging, (ii) <50% arterial stenosis proximal to the infarct, and (iii) no 
major-risk cardio-embolic source (including no permanent or paroxysmal atrial fibrillation 
diagnosed by ECG)16. ESUS comprises about 1 in 6 ischemic strokes17. Since recurrence rate 
of stroke is substantial (4.5% per year) during (mostly) antiplatelet therapy, clear 
identification of its pathogenesis and appropriate anti-thrombotic management are necessary. 
Because subclinical AF (SCAF) may play an important role in the pathogenesis of cardio-
embolic stroke corresponding to ESUS, screening for SCAF with accuracy and efficacy is 
necessary, and that subsequent intervention of SCAF shows net benefit.18. 
Since SCAF can be documented in CI Ds, studies of AF detection in patients with CIEDs 
have demonstrated that the incidence of SCAF varies greatly (28–68%) depending on the 
clinical profile of enrolled patients, follow-up duration, and applied diagnostic criteria18-22. 
Despite the different diagnostic criteria and follow-up periods between studies, all patients 
with SCAF documented in CIEDs showed a 2.1–6.7 fold increase in stroke risk12, 18, 20, 23-26. 
Therefore, patients with CIEDs and SCAF may benefit from close follow-up and risk 
stratification18. For those with SCAF duration ≥24 hours, there is likely a benefit from 
anticoagulation27. In those patients with SCAF duration < 24 hours and clinical risk factors, 
ongoing randomized trials will answer definitively whether anticoagulation of SCAF 
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documented in CIEDs can reduce ischemic stroke and systemic embolism (ARTESiA trial: 
NCT01938248, NOAH trial: NCT02618577)28, 29. 
However, in the absence of CIEDs, such prolonged continuous monitoring is not readily 
available. Therefore, different screening methods are recommended to meet the clinical needs 
of individual patients, such as automated blood pressure monitoring30, 31, ECG or pulse taking 
in patients’ age > 65 years32-35, or short-term ECG recording followed by continuous ECG 
monitoring for at least 72 hours in stroke survivors36, 37.  
 
Wider population screening for AF 
Although natural history and clinical significance of SCAF is not fully clarified, screening for 
SCAF by imaging may be justified by the fact that the development of atrial substrate 
precedes the clinical onset of AF. Furthermore, imaging-based screening may be relevant in 
providing information regarding the potential risk for SCAF amongst ESUS patients during 
follow-up.  Thus far, it is not clear whether earlier detection of SCAF at this pre-clinical 
stage is possible or whether treatment would be beneficial. Therefore, more evidence through 
well-designed studies are needed.  
Generally, there are mainly two different types of screening as follows38: (i) Opportunistic 
approach, where targeted patients are screened on appearance once at a single time point 
measurement, for example, when attending for blood pressure checks, and (ii) Systematic 
approach, whereby general random patients are invited for screening. 
Opportunistic screening allows us to target high risk patient populations that are at risk of 
incident AF39. The first randomised comparison of opportunistic versus systematic screening 
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for AF was the SAFE (Screening for AF in the Elderly) study, which showed that 
opportunistic screening was cost-effective at a cost of £562 per additional case of AF 
detected34, 40. 
As specific screening methods, pulse palpation or automated blood pressure monitoring 
(BPM) have been undertaken and these demonstrate good diagnostic yields in a recent meta-
analysis (pulse palpation: c-index = 0.93 [95% CI: 0.91–0.95]; BPM: c-index = 0.98 [95% CI: 
0.96–0.99])30, 31, 35. Furthermore, we are now in the era when new technologies are available 
that can easily screen for AF. In the SEARCH-AF study, 1,000 participants (≥ 65 years) were 
screened with smartphone-based automated algorithm, which showed good sensitivity 
(98.5 %, CI 92 – 100 %) and specificity (91.4 % (CI 89 – 93 %)41. The REHEARSE-AF 
study using portable ECG monitors (AliveCor Kardia) with remote ECG interpretation 
demonstrated higher incidence of AF compared to routine care (hazard ratio 3.9; 95% CI 1.4–
10.4, P = 0.007) at a cost per AF diagnosis of $1078042. In a more contemporary example of 
opportunistic screening for AF, Chan and Choy performed mass, territory-wide single time 
point AF screening in Hong Kong, whereby amongst 13,122 participants, AF prevalence was 
1.8 % and newly diagnosed AF was 0.8 %43. Although there are several limitations in the 
screening method, nearly half of the patients were newly diagnosed by the smartphone-based 
personal ECG device. Thus, population screening methods have the potential to increase AF 
diagnosis rates at varying costs, and the feasibility and cost-effectiveness of a smartphone-
based screening tool remains unknown. 
Because non-paroxysmal AF patients without clinical symptoms are especially common in 
elderly population, systematic screening of older population may improve the prevalence of 
AF33. However, systematic screening through single ECG recording may underestimate 
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paroxysmal AF. Thus, to detect paroxysmal AF, prolonged ECG monitoring or repeated ECG 
recording is required. As another example of systematic AF screening, 7,173 participants of 
the STROKESTOP study were screened by intermittent ECG recordings over 2 weeks44. Of 
this cohort, 9.3 % had a previous AF diagnosis and AF was found in 0.5 % on their first ECG. 
The final prevalence of AF confirmed by repeated ECG recordings (average 26.4 ECG 
recordings per subject) over 2 weeks was increased to 12.3 %, compared to 9.3 % that was 
reported before the screening exercise. 
Large-scale AF screening studies including more than 5,000 participants are listed and 
summarized in table 1. In terms of the additive diagnostic yield and the number needed to 
screen for one patient with newly diagnosed AF, repeated ECG recording was the most useful 
for screening44. Although it is difficult to make general conclusions about the additive 
diagnostic yield of AF screening, given the different characteristics of the populations studied, 
such as race, age, and screening methods chosen, AF prevalence acquired from screening was 
higher than that of the existing diagnostic framework. Efforts are needed to develop and 
validate screening methods across various populations that are both accurate and cost-
effective, particularly in a publicly-funded universal health care system. 
 
Future perspectives of AF screening 
Due to rapid technological advances and cost savings, systematic population screening for AF 
is becoming an increasingly feasible approach and this might enable us to discover and treat 
more AF patients, previously undetected and untreated. Because it is well known that patients 
with SCAF have higher stroke risk12, 13, 18, 20, it is anticipated that early anticoagulation, when 
carefully determined according to AF burden, may be beneficial in terms of stroke prevention, 
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and prospective studies are investigating this28, 29, 44. With current screening methods, 
diagnoses can only be made after a certain degree of AF is evident.  
Through the accumulation of imaging technologies and related investigations, we have found 
that AF is not merely an abnormal pulse, but a syndrome associated with myocardial 
remodelling represented by progressive atrial fibrosis45, 46. Although the evidence to support 
the imaging-based screening is scarce, Healey et al. demonstrated the predictive value of 
echocardiographic changes in left atrial size for AF in the ASSERT-II trial47. However, the 
extent of left atrial size change may be too small to reflect the degree of atrial remodelling in 
the subclinical stage of AF (HR per centimetre diameter, 1.43; 95% CI 1.11–2.15)47. 
Therefore, the development of more advanced, sensitive and reliable diagnostic imaging 
techniques may facilitate the differentiation of SCAF before the clinical phase of AF (Figure 
1). In order to realize imaging-based screening, more evidence will be needed. Indeed, 
imaging-based screening technology may potentially have several advantages over the ECG 
based approach. Without CIEDs, ECGs can miss SCAF events if they cannot be recorded at 
the time of event, but the possibility of missing an unpredictable SCAF event disappears 
through evaluation of ‘static’ atrial substrate by imaging tools regardless of ‘dynamic’ rhythm 
status. Furthermore, a single examination can assess all objective aspects of substrate, instead 
of repeated recordings over a long period (usually, several dozens or hundreds of recordings 
are required, but are not satisfactory)21, 44. Because imaging for screening will be performed 
when the patient is in sinus rhythm state, commonly issued limitations of atrial imaging 
technology in AF patients are mostly reduced or eliminated, and even more delicate imaging 
acquisition and analysis will be realized in the future AF screening. 
Screening of AF is of great importance in the prevention of ischemic stroke, which is a 
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socially and medically substantial issue. AF screening becomes increasingly feasible given 
the technological advances and more comprehensive understanding of AF pathophysiology. 
Patient perspectives are important, and most patients place great emphasis on stroke 
prevention although adherence to treatment efforts require emphasis and implementation48, 49. 
Only then, all screening efforts will lead to greater AF awareness and detection, as well as an 
improvement in outcomes. 
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Table 1. Large-scale atrial fibrillation screening studies (total number of participants > 5,000) 
Study Number of participants Target population 
Mean 
age  
(yrs.) 
Screening 
tool 
Total AF 
prevalence 
N (%) 
Newly 
diagnosed AF 
N (%) 
NNS 
Furberg et 
al. 199450 5,151 
Random sample of citizens from 
Medicare eligibility lists from four 
US communities 
57.6 12-lead ECG 227 (5.4) 77 (1.5) 67 
Meschia et 
al. 201051 29,861 
Black Americans and residents of the 
southeastern ‘stroke belt region’ in 
the US 
74.0 7- or 12-lead 
ECG 432 (1.4) 174 (0.6) 172 
Svennberg 
et al. 
201544 
7,173 
75-76 year-old population in 
Stockholm county or the Halland 
region in Sweden 
N/A 1-lead ECG, 2/day, 2 weeks 884 (12.3) 218 (3.0) 33 
Chan et al. 
201743 13,122 
Untargeted voluntary participation 
by Hong Kong citizens aged ≥ 18 
years 
64.7 1-lead ECG 239 (1.8) 101 (0.8) 129 
Proietti et 
al. 201652 65,747 
Untargeted voluntary participation 
by Belgian citizens 58.0 1-lead ECG 911 (1.4) 603 (0.9) 109 
AF: atrial fibrillation; NNS: number needed to screen for one patient with newly diagnosed atrial fibrillation; N/A: not applicable. 
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Figure 1. Future of AF screening 
 
AF: atrial fibrillation; SCAF: subclinical atrial fibrillation; ECG: electrocardiography. 
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